The Adapt products have been available in the US their biggest market for a few years and yet to have had any meaningful traction. If you’d bother to do any research you would know Europe has been in shambles for years and although their European approval for 3D is a positive sign it’s not likely to result of in massive sales immediately which is what they need to avoid a CR.
News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-507
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.70 |
Change
-1.350(7.92%) |
Mkt cap ! $301.7M | |||
| Open | High | Low | Value | Volume |
| $16.50 | $16.50 | $15.52 | $571.1K | 35.69K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13 | $15.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.00 | 775 | 2 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |